Citations

Clear

3030 citation(s) found for "Susan, M".

Abstract 37: Highly aggregated lung cancer families reveal a heterogeneous cause for a previous linkage signal on 6q
Moiz, Bilal A., Mandal, Diptasri , Gaba, Colette , Yang, Ping , You, Ming , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Musolf, Anthony M. , Simpson, Claire L. , Andrade, Mariza de , Pinney, Susan M. , Amos, Christopher I. , Bailey‐Wilson, Joan E.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 37-37

10.1158/1538-7445.am2020-37 Get It

Abstract More Americans die every year of lung cancer than any other cancer. While the environmental risks for lung cancer are well understood, the genetic risk factors for this disease are not, even though it has been shown that lung cancer risk aggregates in families. Segregation analyses have confirmed the likelihood of rare, highly penetrant variants affecting lung cancer. Family studies offer a unique opportunity to identify such rare risk variants. We have previously identified a genome-wide significant risk locus for lung cancer using multipoint linkage analysis in highly aggregated lung cancer families. In this study, we performed targeted sequencing on this 6q23-6q27 region on 75 individuals from the 9 most strongly linked families. Parametric two-point linkage analysis using an autosomal dominant model with 10% penetrance for carriers and a 1% phenocopy rate and disease allele frequency of 1% was performed for each family. While we did not find any genome-wide significant results in any of the individual families, we did observe several interesting potential rare risk variants. First, we observed that the significant signal previously observed on 6q is recapitulated in these data but the location of the peak LOD is highly heterogeneous across families and it is likely that each family has a different risk gene. While most of the highest LOD scores were in noncoding variants, we did observe exonic variants with the highest LOD scores in two families (44 and 42). Both variants were rare, with a minor allele frequency (MAF) of approximately 1% and were in LPA and GPR126 respectively. Both these genes have been implicated somatically in lung cancer, however this is the first time that they have been implicated in the germline. While the other families have their highest LOD scores in noncoding variants, some of these genes are also good potential candidate genes including PARK2 (family 30), GRM1 (family 47), and PDE10A (family 102). All three genes have been implicated in lung cancer in some capacity, and this is the first time that GRM1 and PDE10A have been implicated as germline mutations. Again, all these variants are rare (MAF ⇐ 0.01) in the general population, which makes sense for a potential highly penetrant risk variant. In this study, we have elucidated that a previously identified risk locus on 6q25 is heterogeneous in the nine most strongly linked families, with different families appearing to be carrying different risk variants. Many of the top variants in each family are rare variants that are in good potential causal genes that have been identified for the first time here as germline risk variants for lung cancer. Further functional annotation is underway for these variants and some additional linkage analyses using other penetrance matrices may also be performed. Citation Format: Anthony M. Musolf, Claire L. Simpson, Bilal A. Moiz, Mariza de Andrade, Diptasri Mandal, Colette Gaba, Ping Yang, Ming You, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Christopher I. Amos, Joan E. Bailey-Wilson. Highly aggregated lung cancer families reveal a heterogeneous cause for a previous linkage signal on 6q [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 37.
Abstract 3222: The Virtual Molecular Tumor Board of the Variant Interpretation for Cancer Consortium: A systematic gateway connecting cancer genome interpretation and progress in genomic knowledgebases in cancer
Madhavan, Subha , Dientsmann, R., Raca, Gordana , Rieke, Damian , Rogan, Peter K. , Vlachos, Ioannis S. , Walsh, Brian , Vlachos, Ioannis S , Pitel, Beth A. , Rao, Shruti , Fitz, Catherine Del Vecchio , Horak, Peter , King, Ian F. G. , Mockus, Susan M. , Sonkin, Dmitriy , Tamborero, David , Warner, Jeremy L. , Griffith, Malachi , Griffith, Obi L. , Chakravarty, Debyani , Wagner, Alex H.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 3222-3222

10.1158/1538-7445.am2020-3222 Get It

Abstract Comprehensive interpretation of a patient's cancer genome is a cross-disciplinary process requiring the expertise of oncologists, molecular pathologists, genetic counselors, genomic scientists, and bioinformaticians. The Variant Interpretation for Cancer Consortium (VICC) has created a non-clinical forum for the variant interpretation process by connecting experts from multiple academic institutions and industry to create a Virtual Molecular Tumor Board (VMTB). During VICC-VMTB sessions, experts retrospectively discuss de-identified, challenging patient cases in the context of genomic interpretation guidelines to evaluate a patient's profile across several distinct components: genomic variants; disease context; therapeutic history; family history; demographic information; genomic assay information; and variant allele frequency. These components are processed through the prism of publically available knowledge and expertise of VMTB members, resulting in a broad spectrum of clinically relevant assertions about the patient's disease that may be of prognostic, diagnostic, or predictive relevance. Through these evaluations, the VICC-VMTB primarily works as a means of illuminating challenges in genomic interpretation and advancing the objectives of domain-specific VICC working groups. Examples of challenges that have been highlighted by the VICC-VMTB forum include: 1) inconsistent disease and therapy ontologies across resources are being addressed by Disease Harmonization & Drug Harmonization working groups, respectively; 2) use of machine-learning and natural language processing into clinical-grade variant interpretation are being addressed by the AI-Assisted Curation working group; 3) aggregation and harmonization of knowledgebase data into a centralized resource is being addressed by the Data Licensing and Variant Harmonization working groups; 4) inefficiencies in knowledgebase search functions are being addressed by the Search working group; 5) determination of accurate prediction of biological consequences of rare variants is being addressed by the In Silico Interpretation working group; and 6) standardization of genomic variant curation is being addressed by the Knowledge Curation and Interpretation Standards working group. These VICC working groups provide dedicated expert assemblies intended to specifically tackle these challenges, further increasing the breadth for which genomic information can be made useful in cancer variant interpretation. The VICC-VMTB has been a pertinent link between cancer genomes and clinical interpretation. We are confident VICC-VMTB will continue to be a gateway of acceleration and progress needed in the field of cancer interpretation to provide accurate and efficient answers for our patients in the future. Citation Format: Beth A. Pitel, Shruti Rao, Catherine Del Vecchio Fitz, Subha Madhavan, Rodrigo Dientsmann, Peter Horak, Ian King, Susan M. Mockus, Gordana Raca, Damian T. Rieke, Peter Rogan, Dmitriy Sonkin, David Tamborero, Ioannis S. Vlachos, Brian Walsh, Jeremy L. Warner, Malachi Griffith, Obi L. Griffith, Debyani Chakravarty, Alex H. Wagner. The Virtual Molecular Tumor Board of the Variant Interpretation for Cancer Consortium: A systematic gateway connecting cancer genome interpretation and progress in genomic knowledgebases in cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3222.
Abstract 1256: Widespread alterations of chromatin accessibility in chronic lymphocytic leukemia (CLL)
Yan, Huihuang , Tian, Shulan , Kleinstern, Geffen , Li, Xing , Wang, Zhiquan , Boddicker, Nicholas , Slager, Susan L. , Braggio, Esteban

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1256-1256

10.1158/1538-7445.am2020-1256 Get It

Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in western countries that has a strong genetic basis. Using data from both chromatin immunoprecipitation and sequencing (ChIP-seq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq), recent studies have uncovered alterations of chromatin landscape in CLL. However, the spectrum of epigenetic changes and the mechanisms of casualtyare only partially understood. In this study, we used ATAC-seq to profile chromatin accessibility across the two major CLL subtypes, IGHV-mutated (n=19) and IGHV-unmutated (n=22). DNA library of accessible chromatin regions was generated from purified CD5+/CD19+ leukemiacells. All libraries were assessed to have high data quality based on the ENCODE quality metrics. Additionally, publicly available ATAC-seq data (GSE118189 and GSE111015) from total (n=5), memory (n=6) and naïve B cells (n=6) were analyzed in parallel and used as normal reference. ATAC-seq peaks from CLL and normal B cells were merged to generate a consensus list of 107,928 high-confidence peaks that did not overlap ENCODE blacklisted regions, were present in at least two CLL or two normal B-cell samples, and had ≥1 counts-per-million in at least 10% of the samples. Raw read counts were Trimmed Mean of M-values normalized and log2 transformed. K-means clustering of differential peaks revealed an extensive reprogramming of chromatin accessibility landscape in CLL, with over 11,000 lost and nearly 9,000 gained open chromatin regions relative to normal B-cells. In particular, we identified two clusters comprising 1,401 regions that were largely open either in IGHV-mutated(571 peaks) or in IGHV-unmutated CLL (830 peaks). Open chromatin regions gained in IGHV-mutatedwere preferentially linked to genes in the B cell receptor signaling pathway and those in IGHV-mutatedto genes enriched in the interferon type I signaling pathway. These discriminatory regions are highly enriched with DNA binding motifs for transcription factors (TFs) with key roles in B cell development, such as PU.1, AP-1, c-Jun, BATF, and TCF family. In addition, 94% of the 1,401 peaks were located in distal regulatory regions, being ≥2.5 kb away from transcription start sites of genes; two-third of these distal regulatory regions overlapped H3K27ac peaks from CLL patients or immune cell types in the Roadmap reference epigenomes,indicating that enhancers are the prime sites of epigenetic differentiation between the two subtypes. Together, our analyses provide new insights into the global alterations of regulatory regions in CLL. Given the noticeable heterogeneity of chromatin landscape, further integration with histone modifications, TF binding, chromatin interaction, gene expression and genetic variation data are needed to understand the roles of epigenetic dysregulation and its interaction with genetic lesions in CLL pathogenesis. Citation Format: Huihuang Yan, Zhiquan Wang, Shulan Tian, Geffen Kleinstern, Nicholas Boddicker, Xing Li, Susan Slager, Esteban Braggio. Widespread alterations of chromatin accessibility in chronic lymphocytic leukemia (CLL) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1256.
Abstract 1096: Harmonization standards from the Variant Interpretation for Cancer Consortium
Babb, Larry, Liang, Yonghao , Roy, Angshumoy , Brush, Matthew , Lee, Jennifer, Lu, Anna, Coard, Thomas, Ritter, Deborah , Walsh, Brian , Madhavan, Subha , Raca, Gordana , Wagner, Alex H. , Hart, Reece K. , Babb, Larry, Freimuth, Robert R. , Coffman, Adam , Pitel, Beth A. , Rao, Shruti , Mockus, Susan M. , Horak, Peter , King, Ian F. G. , Sonkin, Dmitriy , Chakravarty, Debyani , Griffith, Malachi , Griffith, Obi L.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1096-1096

10.1158/1538-7445.am2020-1096 Get It

Abstract The use of clinical gene sequencing is now commonplace, and genome analysts and molecular pathologists are often tasked with the labor-intensive process of interpreting the clinical significance of large numbers of tumor variants. Numerous independent knowledgebases have been constructed to alleviate this manual burden, however these knowledgebases are non-interoperable. As a result, the analyst is left with a difficult tradeoff: for each knowledgebase used the analyst must understand the nuances particular to that resource and integrate its evidence accordingly when generating the clinical report, but for each knowledgebase omitted there is increased potential for missed findings of clinical significance.The Variant Interpretation for Cancer Consortium (VICC; cancervariants.org) was formed as a driver project of the Global Alliance for Genomics and Health (GA4GH; ga4gh.org) to address this concern. VICC members include representatives from several major somatic interpretation knowledgebases including CIViC, OncoKB, Jax-CKB, the Weill Cornell PMKB, the IRB-Barcelona Cancer Biomarkers Database, and others. Previously, the VICC built and reported on a harmonized meta-knowledgebase of 19,551 biomarker associations of harmonized variants, diseases, drugs, and evidence across the constituent resources.In that study, we analyzed the frequency with which the tumor samples from the AACR Project GENIE cohort would match to harmonized associations. Variant matches increased dramatically from 57% to 86% when broader matching to regions describing categorical variants were allowed. Unlike precise sequence variants with specified alternate alleles, categorical variants describe a collection of potential variants with a common feature, such as “V600” (non-valine alleles at the 600 residue), “Exon 20 mutations” (all non-silent mutations in exon 20), or “Gain-of-function” (hypermorphic alterations that activate or amplify gene activity). However, matching observed sequence variants to categorical variants is challenging, as the latter are typically only described as unstructured text. Here we describe the expressive and computational GA4GH Variation Representation specification (vr-spec.readthedocs.io), which we co-developed as members of the GA4GH Genomic Knowledge Standards work stream. This specification provides a schema for common, precise forms of variation (e.g. SNVs and Indels) and the method for computing identifiers from these objects. We highlight key aspects of the specification and our work to apply it to the characterization of categorical variation, showcasing the variant terminology and classification tools developed by the VICC to support this effort. These standards and tools are free, open-source, and extensible, overcoming barriers to standardized variant knowledge sharing and search. Citation Format: Alex H. Wagner, Reece K. Hart, Larry Babb, Robert R. Freimuth, Adam Coffman, Yonghao Liang, Beth Pitel, Angshumoy Roy, Matthew Brush, Jennifer Lee, Anna Lu, Thomas Coard, Shruti Rao, Deborah Ritter, Brian Walsh, Susan Mockus, Peter Horak, Ian King, Dmitriy Sonkin, Subha Madhavan, Gordana Raca, Debyani Chakravarty, Malachi Griffith, Obi L. Griffith. Harmonization standards from the Variant Interpretation for Cancer Consortium [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1096.
Abstract 1054: Vaccination history and risk of lymphoma and its major subtypes
Kleinstern, Geffen , Robinson, Dennis P. , Thompson, Carrie A. , Allmer, Cristine, Nowakowski, Grzegorz S. , Call, Timothy G. , Ansell, Stephen M. , Larson, Melissa C. , Feldman, Andrew L. , Kay, Neil E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1054-1054

10.1158/1538-7445.am2020-1054 Get It

Abstract Background Factors associated with chronic immune stimulation such as transplantation, autoimmune disorders and chronic infections have been linked to the development of lymphoma, while atopic conditions have been associated with a lower risk of lymphoma. Vaccinations, in part due to their ability to induce immune responses, have been hypothesized to play a role in lymphoma etiology, but there are few studies with mixed results and limited data on lymphoma subtypes. Methods We used a clinic-based study of 2461 newly diagnosed lymphoma cases and 2253 frequency-matched controls enrolled from 2002-2015. Participants self-reported lymphoma risk factors and history of vaccinations for hepatitis A, hepatitis B, chicken pox, yellow fever and influenza. Pathology was centrally reviewed, and included 644 chronic lymphocytic leukemia, 528 follicular (FL), 414 diffuse large B-cell (DLBCL), 170 marginal zone, 127 mantle cell, 119 T-cell, 181 Hodgkin, and 278 other lymphoma subtypes. We used polytomous logistic regression to estimate odds ratio (OR) and 95% confidence intervals (CI) of vaccinations with lymphoma risk overall and for subtypes, adjusting for age, sex, socioeconomic status, body mass, alcohol use, smoking history, recreational sun exposure, and family history of hematological malignancies. Results The median age at diagnosis for lymphoma cases was 64 years (range: 18-93) and 58% were male; the median age at enrollment for controls was 62 years (range: 18-91) and 53% were male. The most common vaccinations among controls were influenza (90%) followed by hepatitis B (41%), hepatitis A (30%), chicken pox (20%), and yellow fever (11%). Vaccination for influenza was inversely associated with lymphoma risk overall (OR=0.75, CI:0.61-0.93, P=0.01), with an inverse trend for increasing number of vaccinations (P=0.0001). In subtype analyses, Influenza vaccination was inversely associated with risk of FL (OR=0.59, CI:0.43-0.80, P=0.001), DLBCL (OR=0.64, CI:0.44-0.92, P=0.02) and other lymphoma subtypes (OR=0.66, CI:0.43-1.00, P=0.05). Vaccination for hepatitis A was inversely associated with lymphoma risk (OR=0.79, CI:0.65-0.96, P=0.02), with no significant subtype-specific associations. No evidence of association with vaccination for hepatitis B (OR=0.95, CI:0.79-1.14) and chicken pox (OR=0.83, CI:0.68-1.02) for lymphoma risk overall or for any subtypes. Although no evidence of an association with vaccination for yellow fever (OR=0.81, CI:0.62-1.06) for lymphoma risk, it was inversely associated with DLBCL risk (OR=0.42, CI:0.22-0.80). Conclusion Vaccination for influenza and hepatitis A were inversely associated with overall lymphoma risk. DLBCL was associated with vaccination for influenza and yellow fever. FL was associated with vaccination for influenza. Understanding the underlying mechanisms for a putative protective effect of certain vaccines could provide new clues to the etiology and prevention of lymphoma. Citation Format: Geffen Kleinstern, Dennis P. Robinson, Carrie A. Thompson, Melissa C. Larson, Cristine Allmer, Grzegorz S. Nowakowski, Timothy G. Call, Stephen M. Ansell, Andrew L. Feldman, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan. Vaccination history and risk of lymphoma and its major subtypes [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1054.
Abstract IA05: Molecular analysis of exceptional response in high-grade serous ovarian cancer
Garsed, Dale W. , Pearce, Celeste Leigh , Pike, Malcolm C. , Goode, Ellen L. , Garsed, Dale W , Pandey, Ahwan , Fereday, Sián , Alsop, Kathryn , Wouters, Maartje C.A. , Saner, Flurina A.M. , Kennedy, Catherine J. , Ramus, Susan J. , Köbel, Martin , DeFazio, Anna , Nelson, Brad H. , Bowtell, David D.L.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: IA05-IA05

10.1158/1557-3265.ovca19-ia05 Get It

Abstract A majority of patients with high-grade serous ovarian cancer (HGSC) develop progressive disease following primary treatment, with a five-year survival rate of approximately 40%, and less than 10% survive more than 10 years. Profound genomic instability, treatment with DNA-damaging drugs, and a large tumor burden promote the development of acquired resistance in a large proportion of patients, including multiple convergent resistant events within individuals. Despite the propensity of HGSC to develop drug resistance, a small proportion of patients with advanced disease at diagnosis become long-term survivors. These exceptional patients include those who had suboptimal surgical clearance, and therefore were not cured surgically, and others who have had no evidence of disease recurrence following initial surgery and adjuvant chemotherapy. Our study, which is part of the international collaborative Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG), seeks to identify molecular, immunologic, and epidemiologic factors that influence long-term survival in HGSC. This presentation describes our genomic and immunologic analysis of exceptional survival of this deadly disease. Patient characteristics and clinical histories were evaluated to identify patients diagnosed with advanced stage (Stage IIIC/IV) and histopathologically confirmed HGSC with greater than 10-year overall survival. Whole-genome sequencing (WGS) was performed on primary tumors (median 78x coverage) and germline samples (median 39x coverage) of 55 long-term survivors. Primary tumor samples were also characterized by RNA sequencing, DNA methylation profiling, and immunohistochemistry. Thirty-eight (69%) of long-term surviving patients had residual disease following surgery, suggestive of highly chemosensitive disease. Most patients (41, 75%) were alive at last follow-up and 26 (47%) were progression free. Somatic mutation burden was higher in primary tumors of long-term survivors relative to controls. Genome-wide mutational signatures were predominantly Signature 3 (associated with homologous recombination deficiency), Signature 1 (age related), and Signatures 5, 8, and 16 (unknown etiology). Inactivation of the tumor suppressor RB1 by structural rearrangements or homozygous deletion was frequent in long-term survivors, with 33% of tumors showing associated loss of RB1 protein expression by immunohistochemistry compared to 13% of unselected HGSC controls (n=207; P = 0.001). In an independent HGSC cohort (n=847), RB1 protein loss was associated with prolonged survival (HR: 0.75, P < 0.001) compared to patients with RB1-positive tumors. Furthermore, co-occurrence of germline mutations in BRCA1 or BRCA2 and RB1 loss was associated with a significantly longer overall survival compared to patients with retained RB1 protein expression and no germline BRCA mutation (HR: 0.44, P < 0.001). Multiplexed immunohistochemical analysis with immune cell panels demonstrated distinct associations with long-term survivors. This study delineates the full landscape of genomic alterations in HGSC of long-term survivors. Our findings indicate that specific mutations are associated with enhanced host immune responses and long-term survival. Citation Format: Dale Garsed, Ahwan Pandey, Sian Fereday, Kathryn Alsop, Maartje Wouters, Flurina Saner, Catherine Kennedy, Celeste Pearce, Malcolm Pike, Susan Ramus, Martin Kobel, Anna deFazio, Ellen Goode, Brad Nelson, David Bowtell. Molecular analysis of exceptional response in high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr IA05.
Abstract B37: Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer
Dicks, Ed , Song, Honglin , Ariff, Amir , Intermaggio, Maria P., Moysich, Kirsten, Odunsi, Kunle , Goode, Ellen L. , Fasching, Peter, Gayther, Simon A. , Pavanello, Marina , Bolithon, Adelyn , Pinese, Mark , Bowtell, David D.L. , Fasching, Peter, Doherty, Jennifer A. , Modugno, Francesmary , Kjær, Susanne K. , Webb, Penelope M. , Wu, Anna M. , DeFazio, Anna , James, Paul A. , Subramanian, Deepak , Campbell, Ian , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: B37-B37

10.1158/1557-3265.ovca19-b37 Get It

Abstract Improving risk prediction and prevention strategies through identifying new susceptibility genes for non-high-grade serous ovarian cancer (non-HGS) would represent an important advance in reducing incidence and mortality. Epithelial ovarian cancer (EOC) has five main histotypes that have distinct pathologies, molecular changes, clinical characteristics, and tissues of origin. They are classified as high-grade serous (HGS), low-grade serous (LGS), clear-cell (CCC), endometrioid (END), and mucinous (MUC). A family history of breast or ovarian cancer is the strongest single risk factor for EOC. Germline mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2 confer EOC risks of 44% and 17% by age 80, respectively. Only 40% of the excess familial risk is known, suggesting there are many other susceptibility genes yet unidentified. The non-HGS histotypes are poorly studied due to limited sample size within individual studies. Thus, families of cases with non-HGS tumors have few risk prediction options. Whole-exome sequencing (WES) analysis was performed on 251 non-HGS cases (56 LGS, 55 CCC, 117 END, 23 MUC). Cases were screened negative for BRCA1/2 mutations and selected for a family history of ovarian or breast cancer, or young onset (<45 years) of ovarian cancer. WES identified 1,278 genes with rare predicted truncating mutation in at least one case. Predicted truncating mutations in cases were compared to 171,584 controls from the Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database (gnomAD). Gene-set enrichment analysis showed enrichment for genes involved in the DNA repair pathway (p=3.08 × 10−7). Twenty-five candidate genes (including 4 DNA repair genes) were selected for validation by targeted sequencing. Five genes important in HGS (BRIP1, FANCM, PALB2, RAD51C, RAD51D) as well as two additional candidates (XRCC2 and XRCC3) were also sequenced. Targeted sequencing was performed on 1,779 cases (669 END, 356 CCC, 327 LGS, 427 MUC) and 1,863 controls from studies in the Ovarian Cancer Association Consortium (OCAC). Library preparation and target enrichment was performed using the Fluidigm Juno System and Illumina sequencing was performed on a NovaSeq 6000 Sequencing System. A case-control analysis of predicted truncating variants in the 32 genes was performed. Using a minimum alternate allele frequency of 30%, we identified a higher frequency of mutations in non-HGS cases than controls in ERCC6 (p=0.034) and IL31RA (p=0.034). ERCC6 is involved in DNA repair and IL31RA is a cytokine receptor. Sanger sequencing validation of variants to confirm these results is ongoing. Several other genes showed suggestive higher frequencies of mutations in cases than controls. A larger case control analysis will be performed to confirm those findings. Identifying novel susceptibility genes for non-HGS may have clinical impact by reducing disease-associated mortality through improving risk prediction, identifying prevention strategies, and developing new targeted treatments. Citation Format: Marina Pavanello, Ed Dicks, Honglin Song, Amir Ariff, Adelyn Bolithon, Maria P. Intermaggio, Mark Pinese, Kirsten Moysich, Kunle O. Odunsi, Ellen Goode, David D. Bowtell, Peter Fasching, Jennifer A. Doherty, Francesmary Modugno, Susanne K. Kjær, Penelope M. Webb, Anna Wu, Anna deFazio, Ovarian Cancer Association Consortium, Paul James, Deepak Subramanian, Ian Campbell, Simon A. Gayther, Paul D.P. Pharoah, Susan J. Ramus. Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr B37.
Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
Mott, Sarah L. , McCarthy, Ashley, Singh, Namrata , Sutamtewagul, Grerk , Slager, Susan L. , Cerhan, James R. , Ballas, Zuhair K. , Link, Brian K.

Mayo Clinic

eJHaem | September 1, 2020 | Volume: 1 | Issue: 2 | Pages: 537-544

10.1002/jha2.95 | PMID 35845010 Get It

AbstractObjectiveTo examine the prevalence of hypogammaglobulinemia in chronic lymphocytic lymphoma (CLL) patients and to test the hypothesis that patients with hypogammaglobulinemia have a distinct clinical profile and outcome.MethodsImmunoglobulin levels (IgA, IgG, IgM, IgE) were measured in newly diagnosed, treatment naïve banked samples of 150 patients with CLL followed prospectively for outcomes. Cox regression models were used to assess the effects of clinical variables on overall survival (OS).ResultsThe median age of the selected CLL cohort was 64 years with a male predominance; 96.2% of the patients were white. Fifty‐nine deaths occurred during a median follow up of 6.8 years. Hypogammaglobulinemia in CLL was common in our cohort with 88 (58.7%, 95% CI: 50.4‐66.6%) patients having a measurable isotype deficiency. The most common Ig deficiency was IgM (44.0%). IgA deficiency or low IgE was associated with higher Rai stages as well as with higher white blood cell counts at presentation. Any immunoglobulin deficiency was not associated with overall survival.ConclusionA significant proportion of treatment‐naïve CLL patients had underlying Ig deficiencies – both in isolation and in isotype combinations. Although a deficiency of IgA or IgE was associated with more severe disease at presentation, the impact of this association was mild.
Abstract IA12: The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer
Millstein, Joshua , Goode, Ellen L. , Talhouk, Aline , Huntsman, David G. , Budden, Timothy , Anglesio, Michael S. , Bowtell, David D.L. , Brenton, James D. , Doherty, Jennifer A. , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: IA12-IA12

10.1158/1557-3265.ovca19-ia12 Get It

Abstract Background: High-grade serous ovarian cancer (HGSOC) is the most common and aggressive epithelial ovarian cancer. HGSOC has poor survival, with five-year survival of less than 40%, as it is often diagnosed at a late stage. The median overall survival (OS) is approximately four years. Prognostic gene expression signatures for HGSOC have been inconsistent and have not been translated into clinical practice. The aim of this study was to develop a robust prognostic signature for HGSOC, in order to identify high-risk patients requiring alternative treatments. Methods: A meta-analysis of 1,455 tumors was performed and 200 prognostic genes were selected for expression profiling. An additional 315 candidate genes were selected from the literature, drug-targetable pathways, and other hypotheses. NanoString expression analysis of the 513 genes was performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue from 3,769 women with HGSOC from the Ovarian Tumor Tissue Analysis (OTTA) Consortium. A prognostic model for 5-year survival was developed using regression-based and machine learning methods. The model was trained on 2,702 tumors and evaluated on an independent set of 1,067 tumors. A NanoString expression analysis was performed on 2,692 additional tumors, for a subset of 218 of the genes, including the prognostic signature. Results: Expression of 276 genes was associated with OS (false discovery rate (FDR) < 0.05) in single-gene analyses adjusted for age, stage, and race. The top five genes were TAP1, ZFHX4, CXCL9, FBN1, and PTGER3 (p << 0.001). A 101-gene prognostic signature was established, where a gain of one standard deviation in the gene expression score conferred a greater than two-fold increase in risk of death (HR (hazard ratio) = 2.35 [2.02, 2.71]; p << 0.001). Median survival by quintile group was 9.5, 5.4, 3.8, 3.2, and 2.3 years. Sensitivity analyses, applying the signature to specific patient groups, showed that the prognostic power of the signature is not explained by residual disease, treatment, BRCA status, or CD8 score. The prognostic signature was enriched in pathways with treatment implications, such as PI3K, GPCR, and immune. This signature is suitable for use in FFPE tumor material and future cases can be assigned an HR from the gene expression score. The signature was developed in cases that did not receive neoadjuvant treatment (NACT); however, application to NACT cases was assessed in the second NanoString expression analysis. Conclusion: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium – Stratified Prognosis of Ovarian Tumors) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. Citation Format: Joshua Millstein, Timothy Budden, Ellen L. Goode, Michael S. Anglesio, Aline Talhouk, OTTA consortium, David G. Huntsman, David D. Bowtell, James D. Brenton, Jennifer A. Doherty, Paul P.D. Pharoah, Susan J. Ramus. The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr IA12.
Abstract A03: PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer
Talhouk, Aline , Goode, Ellen L. , Anglesio, Michael S. , Anglesio, Michael S , George, Joshy , Wang, Chen , Ramus, Susan J. , Doherty, Jennifer A. , Bowtell, David D.L.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: A03-A03

10.1158/1557-3265.ovca19-a03 Get It

Abstract Background: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC) are distinguished by differential immune and stromal infiltration and may provide opportunities for targeted therapies. Integration of molecular subtypes into clinical trials has been hindered by inconsistent subtyping methodology. Methods: Adopting two independent approaches, we derived and internally validated algorithms for molecular subtype prediction from gene-expression array data in 1,650 tumors. We applied resulting models to assign labels to 3829 HGSOCs from the Ovarian Tumor Tissue Analysis (OTTA) consortium evaluated on NanoString. Using the labeled NanoString data, we developed, confirmed, and validated a minimal gene set, clinical-grade test and prediction tool. We also used the OTTA dataset to evaluate associations between molecular subtype, biologic, and clinical features. Findings: The locked-down test included a model with 55 genes that predicted HGSOC molecular subtype with >95% accuracy. Subtype varied between primary and metastatic site taken at the time of primary surgery, and was significantly associated with age, stage, CD8+ lymphocyte infiltration, residual disease, and outcome. In multivariable models, molecular subtypes lose their prognostic significance in the presence of risk factors such as residual disease and BRCA1/2 germline mutations. Interpretation: We validated the Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE, or PrOTYPE, following the Institute of Medicine guidelines for the development of omics-based tests. This simple-to-use, cost-effective, fully defined, and locked-down clinical-grade assay will facilitate molecular subtype stratification into clinical trial design. PrOTYPE will allow for objective assessment of HGSOC molecular subtype predictive value in precision medicine applications. Citation Format: Aline Talhouk, Joshy George, Chen Wang, Ellen Goode, Susan Ramus, Jennifer Doherty, David Bowtell, Michael Anglesio, OTTA Consortium. PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr A03.